Researcher
Simon De Meyer
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Cardiovascular Sciences, Kulak Kortrijk Campus (Department)
Responsible
From1 Aug 2015 → Today - Cardiovascular Sciences, Kulak Kortrijk Campus (Department)
Member
From1 Jan 2013 → Today - Biomedical Sciences Group, Kulak Kortrijk Campus (Section)
Member
From1 Oct 2012 → 31 Dec 2012 - Chemistry, Kulak Kortrijk Campus (Department)
Member
From1 Oct 2010 → 30 Sep 2012 - Faculty of Science, Kulak Kortrijk Campus (Faculty)
Member
From1 Oct 2001 → 30 Sep 2010
Projects
1 - 10 of 43
- Universal Chimeric Antigen Receptor (UniCAR) T-cell therapy: an innovative treatment for autoimmune diseaseFrom5 Apr 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Universal chimeric antigen receptor (uniCAR)-T cell therapy to treat autoimmune diseases: immune mediated thrombotic thrombocytopenic purpura as a model system.From1 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Endothelium-targeted gene therapy for von Willebrand disease using a hybrid adeno-transposon strategyFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Flow cytometer for the Interdisciplinary Research Facility Life Sciences at Campus Kulak KortrijkFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Towards improved thrombolysis in acute ischemic strokeFrom1 Jan 2021 → 31 Oct 2021Funding: BOF - postdoctoral mandates
- Light sheet microscopy for interdisciplinary research in life sciencesFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Development and validation of a novel platform for fast and easy diagnosis of von Willebrand diseaseFrom1 Jan 2021 → 31 Dec 2022Funding: IOF - technology validation in lab
- Towards improved thrombolysis in ischemic stroke exploring novel therapeutic targetsFrom15 Sep 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development of a microfluidic platform for self-governing selection of individual B-cells using bioresponsive hydrogels: a source of fully human therapeutic antibodiesFrom20 Aug 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Thrombosis in COVID-19:dysregulation of the tromboinflammatory VWF/ADAMTS13 axis?From1 Apr 2020 → 31 Mar 2021Funding: IOF - technology validation in lab
Publications
21 - 30 of 141
- Thrombus heterogeneity in ischemic stroke(2021)
Authors: Senna Staessens, Simon De Meyer
Pages: 331 - 339 - The von Willebrand factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice(2021)
Authors: Frederik Denorme, Kim Martinod, Hans Deckmyn, Karen Vanhoorelbeke, Simon De Meyer
Pages: 819 - 828 - Detailed histological analysis of a thrombectomy-resistant ischemic stroke thrombus: a case report(2021)
Authors: Senna Staessens, Raf Sciot, Karen Vanhoorelbeke, Simon De Meyer
- Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura(2021)
Authors: Kadri Kangro, Simon De Meyer, Karen Vanhoorelbeke
Pages: 478 - 488 - Thrombotic thrombocytopenic purpura: from patients literacy to immunoprofiling(2020)
Authors: Leydi Carolina Velásquez Pereira, Karen Vanhoorelbeke, Simon De Meyer
- Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19(2020)
Authors: Senna Staessens, Simon De Meyer
Pages: 1881 - 1884 - Inhibition of adamts13: a novel therapy to treat mechanical circulatory support-induced acquired von willebrand syndrome(2020)
Authors: Shannen Deconinck, Bart Meyns, Simon De Meyer, Karen Vanhoorelbeke
Pages: 3836 - 3836 - von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice(2020)
Authors: Sirima Kraisin, Kim Martinod, Hans Deckmyn, Karen Vanhoorelbeke, Philippe Van den Steen, Simon De Meyer
Pages: 2377 - 2390 - Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura(2020)
Authors: Elien Roose, Charlotte Dekimpe, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke
Pages: 353 - 361 - Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations(2020)
Authors: Senna Staessens, Frederik Denorme, Simon De Meyer
Pages: 467 - 476
Patents
1 - 5 of 5
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction (Inventor)
- Compositions comprising adamts13 for use in methods for the recanalization of occluded blood vessels in an infarction (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)